Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 18.78 EUR 0.43% Market Closed
Market Cap: 905.5m EUR

Operating Margin
Nanobiotix SA

464.8%
Current
129%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
464.8%
=
Operating Profit
-65.3m
/
Revenue
-14m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Nanobiotix SA
PAR:NANO
901.4m EUR
465%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
901.4m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
464.8%
=
Operating Profit
-65.3m
/
Revenue
-14m
What is the Operating Margin of Nanobiotix SA?

Based on Nanobiotix SA's most recent financial statements, the company has Operating Margin of 464.8%.

Back to Top